Buy Ajanta Pharma on decline; target Rs 669: Nirmal Bang

Nirmal Bang is bullish on Ajanta Pharma and has recommended to buy the stock on decline for the target price of Rs 669, in its January 25, 2013 research report.
  • Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead GrowMyMoney IThe Winning Leap SME Special
Moneycontrol

Home » News » Recommendations

Jan 28, 2013, 04.30 PM | Source: Moneycontrol.com

Buy Ajanta Pharma on decline; target Rs 669: Nirmal Bang

Nirmal Bang is bullish on Ajanta Pharma and has recommended to buy the stock on decline for the target price of Rs 669, in its January 25, 2013 research report.

Like this story, share it with millions of investors on M3

Buy Ajanta Pharma on decline; target Rs 669: Nirmal Bang

Nirmal Bang is bullish on Ajanta Pharma and has recommended to buy the stock on decline for the target price of Rs 669, in its January 25, 2013 research report.

Post Your Comments

Share Cancel

(more)

, Nirmal Bang |

Nirmal Bang is bullish on Ajanta Pharma and has recommended to buy the stock on decline for the target price of Rs 669, in its January 25, 2013 research report.

"Ajanta Pharma posted better than expected results with 40% growth in sales. EBITDA margins also improved to 26.1% in Q3FY13 from 23.2% in Q2FY13 and 24.4% in Q3FY12. Sales grew by 39.7% YoY mainly on account of volume growth and aided by weakening rupee. Exports contribution for the quarter was higher at 67% (as against 65% in Q2FY13) due to higher contribution from WHO's anti-malarial program. EBITDA margin rose significantly to 26.1% led by operating leverage and lower cost of materials. PAT grew by 76% yoy and 49% qoq. PAT margins rose by 293 bps yoy and 246 bps qoq. For full year management is guiding for 30% growth with around 22% EBITDA margins.

The company has recently received marketing authorization in UK for Sildenafil tablets (better known as Viagra) for 50mg and 100 mg. Company expects to launch the same in UK post patent expiration in June 2013. Company has filed two more ANDAs with USFDA taking the total number of pending approval to nine and total filings to 11. Company intends to file ~ three more ANDAs in Q4FY13 meeting it annual target of 5-6 ANDAs per year.

Valuation & Recommendation: The stock has surpassed our target price of Rs 441. Considering the continuous outperformance, healthy outlook and recent re-rating we have given a higher multiple of 12x to the stock. Based on our FY14E EPS of Rs 55.7 and multiple of 12x, target price comes to Rs 669, a potential upside of 24%. Hence, we recommend to 'BUY on Decline'," says Nirmal Bang research report.

Quarterly Shifts by Morgan Stanley

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

To read the full report click here

Buy, Hold, Sell ? Hear it first on M3
Buy Ajanta Pharma on decline; target Rs 669: Nirmal Bang

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login